SCOTTSDALE, Ariz., Aug. 13, 2015 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT), a national healthcare operator and franchisor of chiropractic clinics, today reported financial results for the quarter ended June 30, 2015.
Second Quarter 2015 Results Highlights
- Revenues increased 98% in the second quarter to $3.4 million, as compared to the same quarter last year
- System wide Comp Sales1 for the second quarter increased by 35%
- 262 total clinics in operation as of June 30, 2015, an increase of nine clinics from March 31, 2015, and an increase of 47 clinics from June 30, 2014
- Company-owned or managed clinics increased to 23 through June 30, 2015
- Opened first greenfield clinic in Tucson, Ariz. in July, and signed leases to build greenfield clinics in Chicago, Los Angeles and Orange County, Calif.
- Appointment of James Edwards, D.C. as Chief Chiropractic & Compliance Officer re-affirms the Company's commitment to strong standards for safety and effectiveness across its system. Dr. Edwards is former chairman of the Board of Governors of the American Chiropractic Association and past president of the Kansas State Board of Chiropractic
"We are very pleased with the progress we made during the quarter. We added 11 company-owned or managed clinics in the second quarter, bringing the total number of clinics opened at June 30, 2015, to 262, which helped generate strong year over year revenue growth in the quarter," remarked John B. Richards, chief executive officer of The Joint Corp. "We opened our first greenfield clinic in July and are executing well against our strategy of becoming the leader in the national market for core chiropractic adjustment services through the development of conveniently located, private pay, cash/credit cards-only, clinics that truly provide affordable and convenient care."
Mr. Richards continued, "Our recent acquisition of a managed unit in upstate New York, together with the acquisition of the regional developer license for New York State sets the stage for further expansion in the northeast, including the country's number one metropolitan statistical area (MSA), New York. Consistent with our expansion and penetration strategy, I am delighted to announce at this time that the company will be entering the country's third largest MSA, Chicago. We have executed leases in this critical market and expect to open a number of managed clinics in the Chicago area during 2015."
Second Quarter 2015 Financial Results
Revenues for the second quarter of 2015 increased 98% to $3.4 million from $1.7 million in the second quarter of the prior year due to organic growth as well as the acquisition of 23 company-owned or managed clinics through June 30, 2015 and an increase in the number of franchised clinics from 215 at June 30, 2014, to 239 at June 30, 2015. Revenue growth was partially offset by a reduction in initial franchise fees as the result of fewer franchised clinics opening during the second quarter of 2015 compared to the same quarter the previous year.
Total cost of revenues in the second quarter of 2015 increased 43% due primarily to increased regional developer commissions on franchise license terminations in the quarter. Total cost of revenues as a percentage of sales decreased to 23% in the second quarter of 2015 from 32% in the second quarter last year due to the addition of revenue in 2015 from company-owned or managed clinics, along with lower regional developer commissions from fewer clinics opened during the period.
Selling and marketing expenses increased to $0.8 million in the second quarter of 2015 compared to $253,612 in the second quarter last year due to increased advertising fund expense as the Company continues to roll out its national marketing campaign.
General and administrative expenses increased to $3.4 million in the second quarter of 2015, compared to $1.1 million in the second quarter of 2014, due to an increase in the number of employees to support the company's growth initiatives, an increase in professional fees for both acquisition related expenses and public company operations, and to a lesser extent, an increase in occupancy costs primarily due to the acquisition of franchises.
Depreciation and amortization expenses increased for the first quarter of 2015, compared to the same period last year due to the addition of fixed assets and intangible assets relating to acquisitions of franchises and regional developer rights.
Operating loss in the second quarter of 2015 was $(1.8) million, compared to an operating loss of $(0.2) million in the second quarter of 2014. Net loss in the second quarter of 2015 was $(1.9) million, or $(0.19) per share, compared to a net loss of $(133,749) or $(0.03) per share, in the same quarter last year.
Adjusted EBITDA in the second quarter of 2015 was ($1.3) million, compared to ($0.2) million in the same quarter the prior year.
As of June 30, 2015, cash and cash equivalents were $12.6 million, compared to $20.8 million at December 31, 2014.
2015 Financial Guidance
The Joint Corp. is re-affirming full year 2015 guidance as indicated below:
- Total revenues in the range of $13 million to $14 million
- Adjusted EBITDA loss in the range of $(7.1) million to $(7.5) million.
- Net new clinic openings in the range of 65 to 75, including 38 to 42 company-owned or managed clinics and 45 to 55 franchised clinics.
The Joint Corp. management will host a conference call at 11:00 a.m. ET on Friday, August 14, 2015 to discuss results for the 2015 second quarter. The conference call will be accessible by dialing 844-464-3931 (U.S.) or 765-507-2604 (international), and referencing 89641035. A live webcast of the conference call will also be available on the investor relations section of the company's website at www.thejoint.com.
An audio replay will be available two hours after the conclusion of the call through August 21, 2015. The replay can be accessed by dialing (855) 859-2056 or (404) 537-3406. The passcode for the replay is 89641035.
Non-GAAP Financial Information
This earnings release includes a presentation of EBITDA and Adjusted EBITDA, which are non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented within the tables below. The company defines adjusted EBITDA as EBITDA before acquisition-related expenses, as well as stock-based compensation expense. The company defines EBITDA as net income (loss) before net interest, taxes, depreciation and amortization expense.
EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.
1Comp Sales include only the sales from clinics that have been open at least 13 full months and exclude any clinics that have closed.
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our failure to develop or acquire corporate clinics as rapidly as we intend, our failure to profitably operate corporate clinics, and the factors described in "Risk Factors" in The Joint Corps.' Registration Statement on Form S-1. Words such as "anticipates", "believes", "continues", "estimates", "expects", "goal", "objectives", "intends", "may", "opportunity", "plans", "potential", "near-term", "long-term", "projections", "assumptions", "projects", "guidance", "forecasts", "outlook", "target", "trends", "should", "could", "would", "will" and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.
About The Joint Corp.
Based in Scottsdale, Ariz., The Joint Chiropractic is reinventing chiropractic care by making quality alternative healthcare affordable for patients seeking pain relief and ongoing wellness. Our membership plans and packages eliminate the need for insurance, and our no-appointment policy, convenient hours and locations make care more accessible. The Joint performs more than two million spinal adjustments a year across 260+ clinics nationwide. For more information, visit www.thejoint.com, follow us on Twitter @thejointchiro and find us on Facebook, YouTube and LinkedIn.
|THE JOINT CORP. AND SUBSIDIARY|
|CONSOLIDATED BALANCE SHEETS|
|June 30,||December 31,|
|Cash and cash equivalents||$ 12,579,991||$ 20,796,783|
|Accounts receivable, net||458,914||704,905|
|Income taxes receivable||292,730||395,814|
|Note receivable - current portion||17,768||27,528|
|Deferred franchise costs - current portion||597,970||622,800|
|Deferred tax asset - current portion||208,800||208,800|
|Prepaid expenses and other current assets||97,195||375,925|
|Total current assets||14,535,336||23,357,131|
|Property and equipment, net||2,691,042||1,134,452|
|Note receivable, net of current portion and reserve||27,942||31,741|
|Deferred franchise costs, net of current portion||1,894,930||2,574,450|
|Intangible assets, net||2,021,136||153,000|
|Deposits and other assets||118,073||585,150|
|Total assets||$ 24,036,127||$ 28,472,028|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable and accrued expenses||$ 1,452,076||$ 1,271,405|
|Co-op funds liability||281,857||186,604|
|Notes payable - current portion||479,400||--|
|Deferred rent - current portion||98,053||93,398|
|Deferred revenue - current portion||2,080,787||1,957,500|
|Other current liabilities||48,691||50,735|
|Total current liabilities||5,315,689||4,177,586|
|Notes payable, net of current portion||140,000||--|
|Deferred rent, net of current portion||410,755||451,766|
|Deferred revenue, net of current portion||5,734,709||7,915,918|
|Commitments and contingencies|
|Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of June 30, 2015, and December 31, 2014||--||--|
|Common stock, $0.001 par value; 20,000,000 shares authorized, 10,333,534 shares issued and 9,799,534 shares outstanding as of June 30, 2015 and 10,196,502 shares issued and 9,662,502 outstanding as of December 31, 2014||10,333||10,197|
|Additional paid-in capital||21,710,338||21,420,975|
|Treasury stock (534,000 shares as of June 30, 2015 and December 31, 2014, at cost)||(791,638)||(791,638)|
|Total stockholders' equity||12,157,259||15,627,353|
|Total liabilities and stockholders' equity||$ 24,036,127||$ 28,472,028|
|THE JOINT CORP. AND SUBSIDIARY|
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Royalty fees||$ 1,098,190||$ 753,265||$ 2,113,704||$ 1,361,591|
|Revenues and management fees from company clinics||783,016||--||1,170,469||--|
|Advertising fund revenue||339,462||29,376||624,978||116,110|
|IT related income and software fees||197,214||211,200||401,189||410,825|
|Regional developer fees||50,750||116,000||268,250||224,750|
|Cost of revenues:|
|Franchise cost of revenues||743,592||490,298||1,251,158||949,074|
|IT cost of revenues||48,226||63,915||85,921||135,663|
|Total cost of revenues||791,818||554,213||1,337,079||1,084,737|
|Selling and marketing expenses||790,001||253,612||1,757,024||399,778|
|Depreciation and amortization||278,502||48,819||401,098||88,885|
|General and administrative expenses||3,412,484||1,084,346||6,200,726||2,050,640|
|Total selling, general and administrative expenses||4,480,987||1,386,777||8,358,848||2,539,303|
|Loss from operations||(1,846,059)||(209,155)||(3,761,282)||(379,369)|
|Other income (expense), net||(9,811)||(3,800)||1,689||(3,800)|
|Loss before income tax benefit||(1,855,870)||(212,955)||(3,759,593)||(383,169)|
|Income tax benefit||--||79,206||--||121,523|
|Net loss and comprehensive loss||$ (1,855,870)||$ (133,749)||$(3,759,593)||$ (261,646)|
|Loss per share:|
|Basic and diluted loss per share||$ (0.19)||$ (0.03)||$ (0.39)||$ (0.05)|
|Weighted average shares||9,768,230||4,819,902||9,734,115||4,815,754|
|Non-GAAP Financial Data:|
|Depreciation and amortization expense||278,502||48,819||401,098||88,885|
|Tax expense (benefit) penalties and interest||--||(79,206)||--||(121,523)|
|EBITDA||$ (1,574,079)||$ (164,136)||$(3,354,678)||$ (294,284)|
|Acquisition related expenses||136,544||--||279,253||--|
|Adjusted EBITDA||$ (1,280,323)||$ (151,814)||$(2,785,926)||$ (266,362)|
|THE JOINT CORP. AND SUBSIDIARY|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Six Months Ended|
|Net loss||$ (3,759,593)||$ (261,646)|
|Adjustments to reconcile net loss to net cash||180,692||20,219|
|Changes in operating assets and liabilities||1,035,333||515,245|
|Net cash (used in) provided by operating activities||(2,543,568)||273,818|
|Net cash used in investing activities||(5,648,224)||(529,902)|
|Net cash used in financing activities||(25,000)||--|
|Net decrease in cash||$ (8,216,792)||$ (256,084)|
Source:The Joint Corp.